Bevacizumab Fails to Improve Angiosarcoma Outcomes With Paclitaxel
UBM Medica,
Adding bevacizumab to paclitaxel did not improve outcomes in a phase II trial of patients with angiosarcoma.
Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial
Overview of attention for article published in Journal of Clinical Oncology, July 2015
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (89th percentile)
-
Above-average Attention Score compared to outputs of the same age and source (58th percentile)
Readers on
- mendeley
- 109 Mendeley